NYSEAMERICAN:ZOM Zomedica (ZOM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Zomedica Stock (NYSEAMERICAN:ZOM) Get Zomedica alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume790,936 shsAverage Volume4.72 million shsMarket Capitalization$95.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Zomedica is a veterinary health company that develops and commercializes diagnostic and therapeutic products for companion animals. Its offerings are designed to help veterinary practices evaluate and treat animal health conditions. The company’s products include the TRUFORMA point-of-care diagnostic platform, which uses proprietary technology and assays to support testing for conditions in dogs and cats. Zomedica also offers therapeutic technologies, including PulseVet shock wave therapy systems and Assisi Loop devices, which use targeted pulsed electromagnetic field therapy. Founded in 2015 and based in Ann Arbor, Michigan, Zomedica has expanded its product portfolio through acquisitions, including PulseVet. Its products serve veterinary practices in the United States and other markets through sales and distribution channels.AI Generated. May Contain Errors. Read More Receive ZOM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zomedica and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZOM Stock News HeadlinesZomedica Announces "Third Friday at Four" Webinar on November 20, 2026: The People Behind Zomedica - Seven Guiding Principles in Action, and Q3 Financial ResultsNovember 10 at 6:51 AM | finance.yahoo.comZomedica Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMThis Could Be the Biggest Monetary Shift in 50 YearsThe U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trades above $4,000 today. That gap means Washington's books show about $11 billion in gold that is actually worth more than $1 trillion. A bill in Congress would require repricing those reserves at market value. More than 60 million Americans qualify to move part of their savings into physical gold, tax-free and penalty-free, according to the 2026 Gold and Silver Guide.November 13 at 1:00 AM | Patriot Gold Group (Ad)Zomedica Corp. (ZOMDF) Discusses Clinical Program and Evidence-Driven Adoption in Veterinary Products TranscriptOctober 24, 2026 | seekingalpha.comZomedica Corp. (ZOMDF) Inside Marketing: How Demand Creation Drives Revenue and Supports Distinct Product Portfolios TranscriptSeptember 26, 2026 | seekingalpha.comZomedica stringe un accordo con un gruppo veterinario per i suoi prodottiSeptember 23, 2026 | it.investing.comZomedica Corp. (ZOMDF) Q2 2026 Earnings Call TranscriptAugust 28, 2026 | seekingalpha.comZomedica Corp.: Zomedica Announces Strategic Collaboration with Boehringer Ingelheim Animal Health Canada Inc. to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA PlatformAugust 13, 2026 | finanznachrichten.deSee More Headlines ZOM Stock Analysis - Frequently Asked Questions How were Zomedica's earnings last quarter? Zomedica Corp. (NYSEAMERICAN:ZOM) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($0.01) earnings per share for the quarter. The company had revenue of $7 million for the quarter. Zomedica had a negative trailing twelve-month return on equity of 12.47% and a negative net margin of 232.88%. Read the conference call transcript. What other stocks do shareholders of Zomedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zomedica investors own include NIO (NIO), SNDL (SNDL), Bionano Genomics (BNGO), Palantir Technologies (PLTR), Tesla (TSLA), Plug Power (PLUG) and Ocugen (OCGN). Company Calendar Today11/13/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSEAMERICAN:ZOM CIK1684144 Webwww.zomedica.com Phone734-369-2555FaxN/AEmployees50Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.53 million Net Margins-232.88% Pretax Margin-232.24% Return on Equity-12.47% Return on Assets-11.84% Debt Debt-to-Equity RatioN/A Current Ratio10.82 Quick Ratio10.15 Sales & Book Value Annual Sales$25.19 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / BookN/AMiscellaneous Outstanding Shares979,950,000Free Float938,890,000Market Cap$95.35 million OptionableNot Optionable Beta1.03 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSEAMERICAN:ZOM) was last updated on 3/4/2025 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zomedica Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zomedica With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
